Identifying individuals at high risk of Alzheimer’s disease

Dementia affects an estimated 353,800 Australians, with up to 80% being diagnosed with Alzheimer’s disease (AD). Newly developed anti-amyloid drugs are set to revolutionise the treatment of AD. These are likely to have the most impact at the earliest disease stages, therefore there is an urgent need for early-stage biomarkers which are affordable, accessible and scalable.

To generate predictive screening algorithms, opening up opportunities for simple, accurate and effective screening to identify early-stage AD.

The identification of individuals at the earliest stages of AD will provide the opportunity to allow the selection of individuals for early treatment strategies.